Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Laufer

Showing results (101-110 of 123) with videos related to

Pageof 13
Sort By:
PLOS Global Public Health|May 5, 2023
Optimizing next-generation RSV prevention in Mali: A cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxisRachel S Laufer, Ranju Baral, Andrea G Buchwald, et al.
Plos One|September 7, 2018
Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosaNicolas Hegerle, Myeongjin Choi, James Sinclair, et al.
The Journal of Allergy and Clinical Immunology. Global|May 22, 2023
Model-estimated impacts of pediatric respiratory syncytial virus prevention programs in Mali on asthma prevalenceJustin R Ortiz, Rachel S Laufer, Steven M Brunwasser, et al.
Vaccine|September 30, 2023
Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022Meagan C Fitzpatrick, Rachel S Laufer, Ranju Baral, et al.
Plos Neglected Tropical Diseases|April 8, 2017
Development of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan AfricaScott M Baliban, Mingjun Yang, Girish Ramachandran, et al.
Nature Communications|January 16, 2021
The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repairAyesha A Shafi, Chris M McNair, Jennifer J McCann, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IRMeizhong Jin, Prafulla C Gokhale, Andy Cooke, et al.
Vaccine|July 30, 2021
Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisionsRachel S Laufer, Amanda J Driscoll, Ranju Baral, et al.
The Journal of Infectious Diseases|January 13, 2017
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost RegimensJulien Nyombayire, Omu Anzala, Brian Gazzard, et al.
JAMA|October 8, 2014
New Delhi metallo-β-lactamase-producing carbapenem-resistant Escherichia coli associated with exposure to duodenoscopesLauren Epstein, Jennifer C Hunter, M Allison Arwady, et al.
Pageof 13

Showing results (101-110 of 123) with videos related to

Sort By:
Pageof 13
PLOS Global Public Health|May 5, 2023
Optimizing next-generation RSV prevention in Mali: A cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxisRachel S Laufer, Ranju Baral, Andrea G Buchwald, et al.
Plos One|September 7, 2018
Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosaNicolas Hegerle, Myeongjin Choi, James Sinclair, et al.
The Journal of Allergy and Clinical Immunology. Global|May 22, 2023
Model-estimated impacts of pediatric respiratory syncytial virus prevention programs in Mali on asthma prevalenceJustin R Ortiz, Rachel S Laufer, Steven M Brunwasser, et al.
Vaccine|September 30, 2023
Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022Meagan C Fitzpatrick, Rachel S Laufer, Ranju Baral, et al.
Plos Neglected Tropical Diseases|April 8, 2017
Development of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan AfricaScott M Baliban, Mingjun Yang, Girish Ramachandran, et al.
Nature Communications|January 16, 2021
The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repairAyesha A Shafi, Chris M McNair, Jennifer J McCann, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IRMeizhong Jin, Prafulla C Gokhale, Andy Cooke, et al.
Vaccine|July 30, 2021
Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisionsRachel S Laufer, Amanda J Driscoll, Ranju Baral, et al.
The Journal of Infectious Diseases|January 13, 2017
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost RegimensJulien Nyombayire, Omu Anzala, Brian Gazzard, et al.
JAMA|October 8, 2014
New Delhi metallo-β-lactamase-producing carbapenem-resistant Escherichia coli associated with exposure to duodenoscopesLauren Epstein, Jennifer C Hunter, M Allison Arwady, et al.
Pageof 13